Regeneron Pharmaceuticals Inc. buy kasimir
Start price
29.09.15
/
50%
€415.02
Target price
02.02.16
€541.20
Performance (%)
-12.41%
End price
02.02.16
€363.52
Summary
This prediction ended on 02.02.16 with a price of €363.52. The prediction for Regeneron Pharmaceuticals Inc. disappointed with a performance of -12.41%. kasimir has 50% into this predictionRegeneron Pharmaceuticals, Inc. is a biotechnology company that is engaged in the discovery, development, and commercialization of medicines for the treatment of serious medical conditions. The company's products include EYLEA, a treatment for wet age-related macular degeneration and diabetic macular edema; Dupixent, a treatment for atopic dermatitis and asthma; and Libtayo, a treatment for certain types of cancer. Regeneron also has a strong focus on research and development, with a pipeline of potential new treatments for a variety of diseases. The company is headquartered in Tarrytown, New York and trades on the NASDAQ stock exchange under the symbol REGN.
Performance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Regeneron Pharmaceuticals Inc. | 1.525% | 1.525% | -3.086% | -2.831% |
| iShares Core DAX® | 0.224% | 2.457% | 21.634% | 71.886% |
| iShares Nasdaq 100 | 0.371% | -0.320% | 5.422% | 113.046% |
| iShares Nikkei 225® | 0.972% | -0.829% | 15.333% | 47.267% |
| iShares S&P 500 | 0.417% | -0.157% | 3.125% | 68.687% |
Comments by kasimir for this prediction
In the thread Regeneron Pharmaceuticals Inc. diskutieren
Schnäppchenpreis bei Regeneron
Langfristiger Kauf von REGN um die 465$, Ziel 10-20% in 6 Monaten.
(Stop Loss Kurs erreicht)